Dental laser supplier BIOLASE Inc (NASDAQ:BIOL) reported on Tuesday the receipt of US the Food and Drug Administration (FDA) regulatory clearance for the Epic Hygiene laser for Laser Bacterial Reduction (LBR) therapy indication.
US FDA approval for the company's Epic Hygiene laser allows for the early management of periodontal disease utilizing laser light energy to reduce bacteria and thus decreasing inflammation and enhancing periodontal health.
Designed by dental hygienists, the Epic Hygiene laser provides the dental hygienist community with more access to the advantages of laser technology as well as allows to perform gentler, highly effective treatments for bacterial reduction and managing periodontal disease.
The company stated that the Epic Hygiene laser has received clearance for the removal of highly inflamed edematous tissue affected by bacteria penetration of the pocket lining and junctional epithelium.
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP